July 24, 2013

Even though customers may only buy certain OTC categories a few times a year, for consumer healthcare brands, the opportunities to have a more meaningful relationship in the lives of their consumers has never been greater, Stefan Merlo, director of healthcare strategy, Novartis Consumer Health, told DSNtv in a special edition of DSN Executive Viewpoints.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 22, 2014

Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.

December 19, 2014

Dr. Reddy’s Laboratories has announced that it has closed the acquisition of Habitrol brand — an over-the-counter nicotine replacement therapy transdermal patch — from Novartis Consumer Health.

December 19, 2014

The overwhelming majority of GlaxoSmithKline shareholders on Thursday approved the proposed transaction with Novartis.

December 16, 2014

Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use. 

 

December 1, 2014

GlaxoSmithKline last week announced that the Federal Trade Commission has approved GSK's acquisition of Novartis' vaccines business and the creation of a joint consumer care company between GSK and Novartis.

 

December 1, 2014

Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. 

November 20, 2014

Moberg Pharma AB on Thursday announced that Jeff Vernimb has been named general manager for its U.S. operations and a member of Moberg's management team, effective Dec. 15.

 

November 11, 2014

Teva Pharmaceuticals announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 5-mg strength.

November 10, 2014

Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

October 30, 2014

Sandoz, through its branded dermatology business PharmaDerm, and Medigene AG on Thursday announced a promotion agreement with Women's Choice Pharmaceuticals for Veregen (sinecatechins) ointment, 15% strength. 

October 28, 2014

Novartis announced that it has entered into a definitive agreement to divest its influenza vaccines business to CSL for an agreed price of $275 million.

 

October 15, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, recently introduced new executives to its staff.

October 15, 2014

The resurgence of iconic pain relief brands Tylenol and Excedrin continue to contribute to the slight growth across internal analgesic tablets. It’s a $3.2 billion book of business across U.S. multi-outlets, according to IRI, that is up slightly by 0.8% for the 52 weeks ended Aug. 10. 

October 15, 2014

Could the regulatory and scientific logjam that’s keeping copycat biotech medicines off the market and out of the hands of patients and health providers in the United States finally be breaking?

October 14, 2014

Following the completion of a joint venture between GlaxoSmithKline and Novartis' consumer health units, Brian McNamara, currently division head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses.

September 30, 2014

Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths.

September 8, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, introduced new executives to its staff. 

September 2, 2014

Sandoz last week announced the U.S. market introduction of decitabine for injection, a generic version of Eisai’s Dacogen.

August 20, 2014

The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.

August 20, 2014

Excedrin relaunched in the United States in 2013 and is doing well. The brand generated $130 million between its Excedrin tablets and Excedrin Migraine tablets for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.

July 28, 2014

The Food and Drug Administration has accepted a license application by Sandoz, Novartis' generics company, for a potential generic biologic drug, the company announced Monday.

July 15, 2014

Novartis has entered into an agreement with a division of Google to in-license its “smart lens” technology for all ocular medical uses.